Unlabelled iododeoxyuridine increases the cytotoxicity and incorporation of [1251]-iododeoxyuridine in two human glioblastoma cell lines
Details
Serval ID
serval:BIB_A342372F8724
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Unlabelled iododeoxyuridine increases the cytotoxicity and incorporation of [1251]-iododeoxyuridine in two human glioblastoma cell lines
Journal
Nuclear Medicine Communications
ISSN
0143-3636 (Print)
Publication state
Published
Issued date
10/2000
Volume
21
Number
10
Pages
947-53
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Oct
Research Support, Non-U.S. Gov't --- Old month value: Oct
Abstract
Iododeoxyuridine (IUdR), labelled with radioiodines emitting Auger, alpha or beta- radiation, has been proposed as a therapeutic tool in the treatment of cancer. However, the low per cent incorporation in tumour cells and limited cytotoxicity are major obstacles for such an application. Using unlabelled IUdR as a modulator, we have studied the in vitro cytotoxicity of [125I]-IUdR in two human glioblastoma cell lines. Surprisingly, an enhanced cytotoxicity of [125I]-IUdR was observed in the presence of 0.3-10 microM concentrations of unlabelled IUdR in U251 glioblastoma cells and to a lesser extent in LN229 cells. The presence of unlabelled IUdR unexpectedly increased the incorporation of [125I]-IUdR in both cell lines. Thymidine competitively blocked the cytotoxic effects of combined unlabelled and [125I]-labelled IUdR in these cells and DNA-incorporation of radiolabelled IUdR.
Keywords
Binding, Competitive
Cell Survival/radiation effects
DNA, Neoplasm/metabolism
Glioblastoma/metabolism/pathology/*radiotherapy
Humans
Idoxuridine/pharmacokinetics/*therapeutic use
Iodine Radioisotopes/pharmacokinetics/*therapeutic use
Radiopharmaceuticals/pharmacokinetics/*therapeutic use
Tumor Cells, Cultured
Pubmed
Web of science
Create date
25/01/2008 12:27
Last modification date
20/08/2019 16:08